Fat from deceased people has begun to be used to enhance breasts and buttocks

One of the most unusual and controversial trends of recent years has appeared in the aesthetics industry. More and more patients in the US are agreeing to procedures using a special filler made from the fatty tissue of deceased people. The new product has already received the unofficial nickname “zombie filler” and is drawing both interest and admiration, as well as serious questions from doctors and regulators.

The product in question is AlloClae, which is made from donor fatty tissue obtained from people who have bequeathed their organs and tissues after death. The collected material undergoes multi-stage cleaning, sterilization and processing, during which the donor’s cells and DNA are removed. What remains is a kind of protein scaffold that is gradually populated by the patient’s own cells after being injected into the body.

The main advantage of the new technology is the ability to increase the volume of the breasts, buttocks or thighs, or to correct body contours without a full surgical operation, general anesthesia or lengthy recovery. Some patients undergo the procedure literally during their lunch break and return to work just a few hours later. That is why American plastic surgeons call it “lunch break plastic surgery” or “executive surgery.”

Demand for the new product is particularly high among affluent clients and senior executives at major companies. According to surgeons, many patients are willing to pay tens of thousands of dollars for the chance to improve their appearance without disrupting their work schedule. The cost of procedures can range from 10,000 to 100,000 dollars, depending on the amount of material used.

The technology’s popularity is also being driven by the widespread use of GLP-1-based weight-loss drugs such as Ozempic. After significant weight loss, many people are left with reduced breast, buttock and facial volume. For some patients, donor fat has become a way to quickly restore lost contours without liposuction or transplantation of their own fat.

However, not all specialists share the enthusiasm surrounding the new procedure. Doctors stress that the technology has only recently appeared, so there is still not enough data on its long-term safety. Experts point to possible risks, including infections, problems with tissue integration and other complications that require further study.

Ethical questions are also being raised. Some specialists wonder whether donors or their relatives realize that the donated tissues may be used not only to save lives, but also for cosmetic procedures. Manufacturers say they obtain the material only when there is proper consent for the aesthetic use of tissues.

Meanwhile, a legal dispute has already erupted around AlloClae. Authorities in New York State have launched an investigation into the distribution of the product. According to prosecutors, the manufacturer may have supplied the product to the state without the necessary permits. As a result, some batches were seized, and the company itself temporarily suspended shipments to New York until the court proceedings are concluded.

Despite the controversy, interest in “zombie fillers” continues to grow. Many plastic surgeons report long waiting lists, and demand already exceeds production volumes. If the technology proves safe in the long term, it could become one of the most notable directions in modern aesthetic medicine.